RT Journal Article
SR Electronic
T1 Estimating the Prevalence of COVID-19 in the United States: Three Complementary Approaches
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.18.20070821
DO 10.1101/2020.04.18.20070821
A1 Lu, Fred S.
A1 Nguyen, Andre T.
A1 Link, Nick
A1 Santillana, Mauricio
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.18.20070821.abstract
AB Effectively designing and evaluating public health responses to the ongoing COVID-19 pandemic requires accurate estimation of the week to week burden of COVID-19. Unfortunately, a lack of systematic testing across the United States (US) due to equipment shortages and varying testing strategies has hindered the usefulness of the available positive COVID-19 case counts. We introduce three complementary approaches aimed at estimating the prevalence of COVID-19 in each state in the US as well as in New York City. Instead of relying on an estimate from a single data source or method that may be biased, we provide multiple estimates, each relying on different assumptions and data sources. Across our three approaches, there is a consistent conclusion that estimated state-level COVID-19 case counts usually vary from 10 to 100 times greater than the official positive test counts. Nationally, our lowest and highest estimates of COVID-19 cases in the US from March 1, 2020 to April 4, 2020 are 2.7 and 8.3 million (9 to 27 times greater). These estimates are to be compared to the cumulative confirmed cases of about 311,000 as of April 4th. Our approaches demonstrate the value of leveraging existing influenza-like-illness surveillance systems for measuring the burden of new diseases that share symptoms with influenza-like-illnesses. Our methods may prove useful in assessing the burden of COVID-19 in other countries with comparable influenza surveillance systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMS is partially supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R01GM130668. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available. https://www.census.gov/data/tables/time-series/demo/popest/2010s-state-detail.html https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html https://coronavirus.jhu.edu/data https://covidtracking.com/